4.35
+0.04(+0.93%)
Currency In USD
| Previous Close | 4.31 |
| Open | 4.45 |
| Day High | 4.48 |
| Day Low | 4.35 |
| 52-Week High | 21.4 |
| 52-Week Low | 3.65 |
| Volume | 70,182 |
| Average Volume | 51,677 |
| Market Cap | 8.18M |
| PE | -1.08 |
| EPS | -4.02 |
| Moving Average 50 Days | 4.05 |
| Moving Average 200 Days | 7.1 |
| Change | 0.04 |
If you invested $1000 in Neuphoria Therapeutics Inc. (NEUP) since IPO date, it would be worth $24.61 as of March 04, 2026 at a share price of $4.35. Whereas If you bought $1000 worth of Neuphoria Therapeutics Inc. (NEUP) shares 3 years ago, it would be worth $100.69 as of March 04, 2026 at a share price of $4.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees
GlobeNewswire Inc.
Dec 08, 2025 1:00 PM GMT
Company Urges Shareholders to Follow ISS’ Recommendation and Vote the WHITE Proxy Card BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology c
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium
GlobeNewswire Inc.
Dec 04, 2025 1:00 PM GMT
Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card BURLINGTON, Mass., Dec. 04, 2025 (GLOBE N
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions
GlobeNewswire Inc.
Dec 01, 2025 1:00 PM GMT
BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals a